Get started
Work

Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas

Year: 2018
Type: article
Abstract: Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.
DOI: 10.4155/fmc-2018-0163
Authors: Jaclyn J Renfrow, Michael H Soike, Waldemar Debinski, Shakti H Ramkissoon, Ryan T Mott, Mark B Frenkel, Jann N Sarkaria, Glenn J Lesser, Roy E Strowd
Institutions: Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Wake Forest University Health Sciences, Foundation Medicine (United States), Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)
Language: English
Subfield: Cancer Research
Open Access status: green
Award: G424083508
OpenAlex ID: W2886561153
FWCI: 1.219
Cites: 85
Cited by: 39
Related to: 10